ArticleMetabolites2013
Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention.
Article in Metabolites, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Monitoring Vitamin BNutrients · 2019Trial
- Non-Hormonal Therapy for Endometriosis Based on Angiogenesis, Oxidative Stress and Inflammation.International journal of fertility & sterility · 2024Review
- Metformin inhibits gastric cancer cell proliferation by regulation of a novel Loc100506691-CHAC1 axis.Molecular therapy oncolytics · 2021Article
- Preclinical meritorious anticancer effects of Metformin against breast cancer: AnJournal of Taibah University Medical Sciences · 2021Article
- Cucurbitacin B Suppresses Hyperglycemia Associated with a High Sugar Diet and Promotes Sleep inMolecules and cells · 2021Article
- Investigation of the Phytochemical Composition, Antioxidant Activity, and Methylglyoxal Trapping Effect ofMolecules (Basel, Switzerland) · 2020Article
- Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.Pigment cell & melanoma research · 2018Review
- Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer: A retrospective study.Medicine · 2017Article
- Effects of turmeric curcuminoids and metformin against central sensitivity to pain in mice.Journal of traditional and complementary medicine · 2017Article
- Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis.International journal of molecular sciences · 2017Article
- The Influence of Chitosan Cross-linking on the Properties of Alginate Microparticles with Metformin Hydrochloride-In Vitro and In Vivo Evaluation.Molecules (Basel, Switzerland) · 2017Article
- The Role of Advanced Glycation End-Products in Cancer Disparity.Advances in cancer research · 2017Review
- Chinese Herbal Medicine Fuzheng Kang-Ai Decoction Inhibited Lung Cancer Cell Growth through AMPKα-Mediated Induction and Interplay of IGFBP1 and FOXO3a.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- The double trouble of metabolic diseases: the diabetes-cancer link.Molecular biology of the cell · 2015Article
- Clinical benefits of metformin in gynecologic oncology.Oncology letters · 2015Article
- Article
- Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Review
- microRNAs and cancer metabolism reprogramming: the paradigm of metformin.Annals of translational medicine · 2014Review
- LOC100506691 Is an Oncogenic Long Noncoding RNA that Promotes Growth and Motility of Lung Cancer Cells.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer metabolism is the focus of intense research, which witnesses its key role in human tumors. Diabetic patients treated with metformin exhibit a reduced incidence of cancer and cancer-related mortality. This highlights the possibility that the tackling of metabolic alterations might also hold promising value for treating cancer patients. Here, we review the emerging role of metformin as a paradigmatic example of an old drug used worldwide to treat patients with type II diabetes which to date is gaining strong in vitro and in vivo anticancer activities to be included in clinical trials. Metformin is also becoming the focus of intense basic and clinical research on chemoprevention, thus suggesting that metabolic alteration is an early lesion along cancer transformation. Metabolic reprogramming might be a very efficient prevention strategy with a profound impact on public health worldwide.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.